Ebb & Flow

When Guilford (GLFD) licensed its GPI 1485 neuroimmunophilin ligand to Symphony Neuro Developmentlast year, the move was designed to let GLFD focus on starting Phase III trials of its Aquavan sedative. But the four Phase III trials of Aquavan were put on hold last week because of adverse events seen in one of the studies

With the future of Aquavan now up in the air, the neuroimmunophilin program is a logical fallback. Both GLFD and Symphony Capital note that the future of GPI 1485 will be determined solely by its Phase II data...